No Data
Shuangcheng Pharmaceuticals Scraps Plan to Acquire Aura Semiconductor Via Share Issuance
The "king of monsters" in the A-shares has fallen: Hainan Shuangcheng Pharmaceuticals has terminated its restructuring late at night, potentially facing a delisting crisis.
The sky has fallen.
The late-night announcement of the "Demon King" triggered a "Moment of Crisis" as Hainan Shuangcheng Pharmaceuticals' restructuring failure sounded the alarm for (Delisted).
1. Hainan Shuangcheng Pharmaceuticals suddenly announced at midnight that it would terminate the acquisition of Aola shares. After planning this Trade last year, the stock price once surged 7 times with "21 boards in 23 days"; 2. The cost differences of the equity obtained by the 25 counterparties faced by the company are significant, and the cost pressure for institutions that entered during Pre-IPO financing may be higher; 3. The company's operating situation is poor and is facing Special Treat, and the failed restructuring may push it into a more dangerous situation.
Hainan Shuangcheng Pharmaceuticals (002693.SZ) terminates the additional issuance and acquisition of Ningbo Aura shares related matters.
Hainan Shuangcheng Pharmaceuticals (002693.SZ) announced that the company previously planned to issue shares and pay Cash / Money Market to Hong...
Despite Currently Being Unprofitable, Hainan Shuangcheng Pharmaceuticals (SZSE:002693) Has Delivered a 198% Return to Shareholders Over 3 Years
Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s (SZSE:002693) Popularity With Investors Under Threat As Stock Sinks 28%
Here's Why Hainan Shuangcheng Pharmaceuticals (SZSE:002693) Can Afford Some Debt
